The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations.

PubWeight™: 0.82‹?›

🔗 View Article (PMC 3980619)

Published in Cancers (Basel) on January 13, 2014

Authors

Xavier Bisteau1, Matias J Caldez2, Philipp Kaldis3

Author Affiliations

1: Institute of Molecular and Cell Biology (IMCB), A*STAR (Agency for Science, Technology and Research), 61 Biopolis Drive, Proteos#3-09, Singapore 138673, Singapore. xbisteau@imcb.a-star.edu.sg.
2: Institute of Molecular and Cell Biology (IMCB), A*STAR (Agency for Science, Technology and Research), 61 Biopolis Drive, Proteos#3-09, Singapore 138673, Singapore. mjcaldez@imcb.a-star.edu.sg.
3: Institute of Molecular and Cell Biology (IMCB), A*STAR (Agency for Science, Technology and Research), 61 Biopolis Drive, Proteos#3-09, Singapore 138673, Singapore. kaldis@imcb.a-star.edu.sg.

Articles cited by this

(truncated to the top 100)

Global cancer statistics. CA Cancer J Clin (2011) 185.92

Hallmarks of cancer: the next generation. Cell (2011) 140.01

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78

CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83

Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (1999) 20.34

Hepatocellular carcinoma. N Engl J Med (2011) 19.40

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93

Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev (1998) 12.55

The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A (1999) 10.75

Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell (1996) 8.77

A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell (1996) 8.41

Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36

FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer (2008) 7.93

Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell (1996) 7.69

Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42

New functional activities for the p21 family of CDK inhibitors. Genes Dev (1997) 6.97

Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer (2006) 6.76

Liver regeneration. J Cell Physiol (2007) 6.69

Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene (2006) 6.61

Cyclin D as a therapeutic target in cancer. Nat Rev Cancer (2011) 5.76

MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61

The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J (1999) 5.44

Deregulated cyclin E induces chromosome instability. Nature (1999) 4.75

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol (2007) 4.73

Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol (1998) 4.54

Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature (2004) 4.35

MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene (2008) 4.11

Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature (1990) 4.10

p21-containing cyclin kinases exist in both active and inactive states. Genes Dev (1994) 4.08

A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat Protoc (2008) 4.02

Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol Cell (2007) 3.97

Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95

Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell (2003) 3.91

MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res (2009) 3.83

FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79

Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta (2002) 3.77

Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology (2002) 3.59

Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol (2009) 3.55

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett (2004) 3.17

A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol (2008) 2.91

Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer (2013) 2.87

Hepatocellular carcinoma. J Hepatol (2000) 2.77

Cycling to cancer with cyclin D1. Cancer Biol Ther (2002) 2.58

MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology (2009) 2.57

Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56

Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol (2005) 2.54

Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene (2006) 2.49

Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J Cell Biol (2004) 2.48

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42

Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest (2008) 2.26

Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol Cell Biol (1994) 2.19

APC/C and SCF: controlling each other and the cell cycle. Curr Biol (2004) 2.14

Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology (1998) 1.97

The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell (2005) 1.90

Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res (1991) 1.89

Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85

Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene (2006) 1.84

Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci (2008) 1.81

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst (2012) 1.81

Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett (2008) 1.80

Cyclin-dependent kinases: a family portrait. Nat Cell Biol (2009) 1.80

Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med (2000) 1.79

Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver. Oncogene (1998) 1.78

Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell (2008) 1.75

Comparative and integrative functional genomics of HCC. Oncogene (2006) 1.75

Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. Cell Cycle (2010) 1.74

Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74

Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin. Hepatology (2010) 1.71

Changes in WNT/beta-catenin pathway during regulated growth in rat liver regeneration. Hepatology (2001) 1.71

Association of cyclin D1 expression with factors correlated with tumor progression in human hepatocellular carcinoma. J Gastroenterol (1999) 1.70

Beta-catenin is temporally regulated during normal liver development. Gastroenterology (2004) 1.69

Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer (2003) 1.67

Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci U S A (1997) 1.67

Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res (1994) 1.63

Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology (2008) 1.62

Cyclin A overexpression induces chromosomal double-strand breaks in mammalian cells. Cell Cycle (2009) 1.62

Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol (2010) 1.61

Hepatocellular carcinoma: global epidemiology. Dig Liver Dis (2001) 1.58

Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res (2001) 1.58

Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration. Proc Natl Acad Sci U S A (2012) 1.55

Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy. Cancer Res (2005) 1.54

Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. Gene (1998) 1.50

Deciphering the retinoblastoma protein phosphorylation code. Trends Biochem Sci (2012) 1.46

Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors. Trends Cell Biol (2011) 1.46

The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div (2012) 1.46

Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol (2013) 1.40

High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene (1999) 1.40

Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics (2011) 1.39

Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun (1993) 1.38

RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology (2007) 1.36

Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res (1994) 1.34

SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology (2009) 1.33

Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. Evidence of a mitogen restriction point in mid-late G1. J Biol Chem (1996) 1.33

Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells. Mol Cell (2008) 1.32

Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut (2001) 1.30

Cyclin D1 promotes mitogen-independent cell cycle progression in hepatocytes. Cell Growth Differ (1999) 1.29

Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog (2007) 1.29